These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 35676019)

  • 1. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.
    Tasavon Gholamhoseini M; Sharafi H; Hl Borba H; Alavian SM; Sabermahani A; Hajarizadeh B
    BMJ Open; 2022 Jun; 12(6):e058757. PubMed ID: 35676019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
    PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
    Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
    Front Public Health; 2021; 9():779215. PubMed ID: 34957030
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China.
    Yun H; Zhao G; Sun X; Shi L
    BMJ Open; 2020 Aug; 10(8):e035224. PubMed ID: 32819983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Goel A; Chen Q; Chhatwal J; Aggarwal R
    J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.
    Wei X; Zhao J; Yang L
    BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33246983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
    Chan J; Kim JJ; Barrett BK; Hamadeh A; Feld JJ; Wong WWL
    J Viral Hepat; 2021 Feb; 28(2):260-267. PubMed ID: 33065774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.
    Virabhak S; Yasui K; Yamazaki K; Johnson S; Mitchell D; Yuen C; Samp JC; Igarashi A
    J Med Econ; 2016 Dec; 19(12):1144-1156. PubMed ID: 27348464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
    Chen P; Jin M; Cao Y; Li H
    Appl Health Econ Health Policy; 2021 May; 19(3):371-387. PubMed ID: 33210262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
    Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
    Restelli U; Alberti A; Lazzarin A; Bonfanti M; Nappi C; Croce D
    Eur J Health Econ; 2018 Jan; 19(1):37-44. PubMed ID: 28008546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.
    Bwa AH; Nangia G; Win STS; Maung ST; Han KAW; Htar SS; Wine LY; Ko WW; Oo MP; Hlaing NKT; Palecki J; Loza BL; Win KM; Reddy R
    J Clin Exp Hepatol; 2019; 9(3):283-293. PubMed ID: 31360020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States.
    Gordon S; Lee J; Smith N; Dieterich D
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):251-257. PubMed ID: 31204882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
    Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
    Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
    Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.